Communiqués Daxor Corporation

Actions

DXR

US2394671034

Cours en clôture Nasdaq Autres places de cotation 00:00:00 12/07/2024			Varia. 5j.	Varia. 1 janv.
9,2 ^USD	+1,21 %		+4,72 %	-4,17 %

11/07	Le diagnostiqueur de volume sanguin BVA-100 ? de Daxor Corporation s'étend à trois nouveaux centres. de Daxor Corporation s'étend à trois nouveaux centres et gagne en popularité à l'échelle nationale.	CI
05/06	Daxor Corporation nomme John L. Jefferies au poste de directeur médical	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide	11/07	AQ
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting	18/06	AQ
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer	05/06	AQ
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	16/04	AQ
Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Spring'24 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic	16/04	AQ
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)	15/04	AQ
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	10/04	AQ
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24	01/04	AQ
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics	25/03	AQ
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024	22/03	AQ
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023	18/03	AQ
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	18/03	AQ
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	11/03	AQ
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients	08/03	AQ
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference	26/02	AQ
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions	12/02	AQ
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts	07/02	AQ
Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting	29/01	AQ
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress	16/01	AQ
DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES	09/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Daxor Corporation

Actions

DXR

US2394671034

Communiqués

Filtres